Ruxolitinib is being tested in clinical trials for patients with JAK-STAT activating mutations as seen in BCR/ABL-like ALL and T-ALL (including ETP-ALL) [53]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.